Clinical Trial Update: A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating eptinezumab in adolescents aged 12-17 years with chronic migraine is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• VYEPTI (eptinezumab)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Chronic Migraine in Children | Phase 3 | Status: RECRUITING